Pandox AB Series B
Pandox AB (publ), a hotel property company, owns, develops, and leases hotel properties. The company operates in two segments, Leases and Own Operations. The Leases segment leases hotels to hotel operators. The Own Operations segment owns hotel properties; and operates hotels. It has operations in Sweden, Denmark, Norway, Finland, Germany, Belgium, the United Kingdom, Ireland, and internationally… Read more
Market Cap & Net Worth: Pandox AB Series B (0R8U)
Pandox AB Series B (LSE:0R8U) has a market capitalization of $152.39K (Skr1.71 Million) as of March 19, 2026. Listed on the LSE stock exchange, this UK-based company holds position #6183 globally and #161 in its home market, demonstrating a 1.89% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pandox AB Series B's stock price Skr188.50 by its total outstanding shares 9069 (9.07K).
Pandox AB Series B Market Cap History: 2015 to 2026
Pandox AB Series B's market capitalization history from 2015 to 2026. Data shows growth from $105.94K to $152.39K (5.74% CAGR).
Pandox AB Series B Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pandox AB Series B's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Pandox AB Series B's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $101.59K | $3.94 Billion | $2.20 Billion | 0.00x | 0.00x |
| 2017 | $114.65K | $4.27 Billion | $3.14 Billion | 0.00x | 0.00x |
| 2018 | $108.91K | $5.12 Billion | $2.82 Billion | 0.00x | 0.00x |
| 2019 | $164.45K | $5.55 Billion | $2.71 Billion | 0.00x | 0.00x |
| 2020 | $112.96K | $3.18 Billion | -$1.40 Billion | 0.00x | N/A |
Competitor Companies of 0R8U by Market Capitalization
Companies near Pandox AB Series B in the global market cap rankings as of March 19, 2026.
Key companies related to Pandox AB Series B by market ranking:
- Shandong Weigao Group Medical Polymer Company Limited (F:UK2): Ranked #6174 globally with a market cap of $1.36 Billion USD ( €1.32 Billion EUR).
- PT Kalbe Farma Tbk (PINK:PTKFF): Ranked #6175 globally with a market cap of $1.36 Billion USD.
- SNGN Romgaz SA (LSE:SNGR): Ranked #6184 globally with a market cap of $1.35 Billion USD.
- Shandong Xinchao Energy Co Ltd (SHG:600777): Ranked #6185 globally with a market cap of $1.35 Billion USD ( CN¥9.91 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #6174 | Shandong Weigao Group Medical Polymer Company Limited | F:UK2 | $1.36 Billion | €0.55 |
| #6175 | PT Kalbe Farma Tbk | PINK:PTKFF | $1.36 Billion | $0.08 |
| #6184 | SNGN Romgaz SA | LSE:SNGR | $1.35 Billion | $1.17 |
| #6185 | Shandong Xinchao Energy Co Ltd | SHG:600777 | $1.35 Billion | CN¥4.97 |
Pandox AB Series B Historical Marketcap From 2015 to 2026
Between 2015 and today, Pandox AB Series B's market cap moved from $105.94K to $ 152.39K, with a yearly change of 5.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr152.39K | -6.89% |
| 2025 | Skr163.67K | +5.94% |
| 2024 | Skr154.49K | +31.97% |
| 2023 | Skr117.06K | +29.58% |
| 2022 | Skr90.34K | -19.64% |
| 2021 | Skr112.42K | -0.48% |
| 2020 | Skr112.96K | -31.31% |
| 2019 | Skr164.45K | +50.99% |
| 2018 | Skr108.91K | -5.01% |
| 2017 | Skr114.65K | +12.86% |
| 2016 | Skr101.59K | -4.11% |
| 2015 | Skr105.94K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Pandox AB Series B was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $152.39K USD |
| MoneyControl | $152.39K USD |
| MarketWatch | $152.39K USD |
| marketcap.company | $152.39K USD |
| Reuters | $152.39K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.